Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 8,8x - 9,7x | 9,3x |
| Selected Fwd Revenue Multiple | 7,7x - 8,5x | 8,1x |
| Fair Value | ₹2.026 - ₹2.226 | ₹2.126 |
| Upside | -26,0% - -18,7% | -22,4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Lupin Limited | 500257 | BSE:500257 |
| Alembic Pharmaceuticals Limited | 533573 | BSE:533573 |
| Medico Remedies Limited | 540937 | BSE:540937 |
| Zydus Lifesciences Limited | 532321 | BSE:532321 |
| Glenmark Pharmaceuticals Limited | 532296 | BSE:532296 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | NSEI:GLAXO |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | |||
| BSE:500257 | BSE:533573 | BSE:540937 | BSE:532321 | BSE:532296 | NSEI:GLAXO | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 6.4% | 9.6% | 8.2% | 8.2% | 5.1% | 2.0% | ||
| 3Y CAGR | 9.7% | 4.9% | 5.8% | 10.7% | 4.9% | 5.7% | ||
| Latest Twelve Months | 12.9% | 4.9% | 14.7% | 16.9% | 6.1% | 11.9% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | 10.1% | 14.7% | 4.4% | 18.9% | 13.6% | 22.0% | ||
| Prior Fiscal Year | 5.1% | 7.7% | 4.9% | 16.6% | 9.8% | 23.0% | ||
| Latest Fiscal Year | 13.9% | 10.6% | 6.9% | 23.2% | 11.4% | 24.3% | ||
| Latest Twelve Months | 18.8% | 11.2% | 6.6% | 24.6% | 18.7% | 27.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 4.12x | 2.84x | 3.21x | 3.92x | 3.03x | 11.94x | ||
| EV / LTM EBIT | 21.9x | 25.5x | 48.5x | 15.9x | 16.2x | 42.9x | ||
| Price / LTM Sales | 4.09x | 2.70x | 3.14x | 3.92x | 3.03x | 12.51x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 2.84x | 3.21x | 4.12x | |||||
| Historical EV / LTM Revenue | 6.30x | 7.51x | 9.46x | |||||
| Selected EV / LTM Revenue | 8.82x | 9.28x | 9.75x | |||||
| (x) LTM Revenue | 37,046 | 37,046 | 37,046 | |||||
| (=) Implied Enterprise Value | 326,648 | 343,840 | 361,033 | |||||
| (-) Non-shareholder Claims * | 20,960 | 20,960 | 20,960 | |||||
| (=) Equity Value | 347,609 | 364,801 | 381,993 | |||||
| (/) Shares Outstanding | 169.4 | 169.4 | 169.4 | |||||
| Implied Value Range | 2,051.93 | 2,153.41 | 2,254.90 | |||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2,051.93 | 2,153.41 | 2,254.90 | 2,739.25 | ||||
| Upside / (Downside) | -25.1% | -21.4% | -17.7% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | |
| Enterprise Value | 905,190 | 182,703 | 4,845 | 849,008 | 422,648 | 443,085 | |
| (+) Cash & Short Term Investments | 29,123 | 1,290 | 15 | 24,950 | 18,202 | 21,108 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Debt | (34,425) | (10,664) | (114) | (1,905) | (17,808) | (148) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 899,888 | 173,329 | 4,746 | 872,053 | 423,042 | 464,045 | |
| (/) Shares Outstanding | 456.5 | 196.6 | 83.0 | 1,006.2 | 282.2 | 169.4 | |
| Implied Stock Price | 1,971.10 | 881.80 | 57.19 | 866.65 | 1,499.15 | 2,739.25 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1,971.10 | 881.80 | 57.19 | 866.65 | 1,499.15 | 2,739.25 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |